Medical
Biopharmaceutical
Pharmaceutical

Lexicon Pharmaceuticals

$5.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.25 (-4.42%) Today
-$0.11 (-2.03%) After Hours

Why Robinhood?

You can buy or sell LXRX and other stocks, options, ETFs, and crypto commission-free!

About

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. Read More The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Employees
174
Headquarters
The Woodlands, Texas
Founded
1995
Market Cap
599.38M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
623.61K
High Today
$5.72
Low Today
$5.34
Open Price
$5.72
Volume
709.03K
52 Week High
$13.97
52 Week Low
$4.25

Collections

Medical
Biopharmaceutical
Pharmaceutical
Health
Biotechnology
Therapy
Technology
US

News

Yahoo Finance5h

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm

NEW YORK, NY / ACCESSWIRE / March 26, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc.

50
Yahoo Finance5h

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX

NEW YORK, NY / ACCESSWIRE / March 26, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc.

17
Yahoo FinanceMar 25

Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug

Shares of Lexicon Pharmaceuticals, Inc. LXRX plunged almost 22% on Mar 22 following a complete response letter (“CRL”) to the new drug application (“NDA”) seeking approval of its lead pipeline candidate, Zynquista (sotagliflozin). Lexicon is developing the candidate in collaboration with Sanofi SNY. Zynquista is a dual SGLT1 and SGLT2 inhibitor evaluated in combination with insulin for the treatment of type I diabetes in adult patients. Lexicon’s shares have decreased 6.6% so far this year against the ind...

332

Earnings

-$0.44
-$0.35
-$0.25
-$0.16
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.29 per share
Actual
-$0.16 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.